MSA-2 | STING agonist

MSA-2 chemical structure

Available Options

Size:PriceQuantity 
5 mg$75.00
25 mg$250.00
Request Quote / Bulk / Custom Size
Product Inquiry

MSA-2 (129425-81-6) is a non-nucleotide-based orally available STING agonist.2 The active agent is a non-covalent dimer that forms in solution. It displays substantially higher potency in an acidified tumor microenvironment.1 It reversed anti-PD-1 therapy resistance in cervical cancer.2 MSA-2 displayed efficacy against clear cell renal cell carcinoma3 and enhanced natural killer cells against breast cancer stem cells4.

References/Citations:

  1. Pan et al. (2020), An orally available non-nucleotide STING agonist with antitumor activity; Science 369 eaba6098
  2. Li et al. (2024), STING agonist inflames the cervical cancer immune microenvironment and overcomes ant-PD-1 therapy resistance; Front. Immunol. 15 1342647
  3. Wang et al. (2024), STING agonist, MSA-2. Inhibits clear cell renal cell carcinoma through improving tumor microenvironment; Mol. Cell Biochem. 479 1697
  4. Bushnell et al. (2024), Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy; Cancer Res. 84 3337
129425-81-6, MSA-2, MSA-2 supplier, Non-nucleotide STING agonist, STING agonist

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

MSA-2 (129425-81-6) is a non-nucleotide-based orally available STING agonist.2 The active agent is a non-covalent dimer that forms in solution. It displays substantially higher potency in an acidified tumor microenvironment.1 It reversed anti-PD-1 therapy resistance in cervical cancer.2 MSA-2 displayed efficacy against clear cell renal cell carcinoma3 and enhanced natural killer cells against breast cancer stem cells4.

References/Citations:

  1. Pan et al. (2020), An orally available non-nucleotide STING agonist with antitumor activity; Science 369 eaba6098
  2. Li et al. (2024), STING agonist inflames the cervical cancer immune microenvironment and overcomes ant-PD-1 therapy resistance; Front. Immunol. 15 1342647
  3. Wang et al. (2024), STING agonist, MSA-2. Inhibits clear cell renal cell carcinoma through improving tumor microenvironment; Mol. Cell Biochem. 479 1697
  4. Bushnell et al. (2024), Natural Killer Cell Regulation of Breast Cancer Stem Cells Mediates Metastatic Dormancy; Cancer Res. 84 3337